• Clinical Insights

4 things to know about Spravato® (Intranasal esketamine)

Aug 9th, 2023

Looking for information on Spravato®? Here are four things you should know.

Spravato®: What, why and how?

Spravato® is an FDA-approved nasal spray indicated for the treatment of treatment-resistant depression in adults and for the treatment of depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior. The way that Spravato® works is not completely understood, but it is thought to be through NMDA (N-methyl-D-aspartate) receptor antagonism, which affects GABA and glutamate, the most abundant neurotransmitter in the brain. Patients generally experience a quick onset of action, with results occurring within a few days or weeks1.

Watch to learn more about Spravato®:

To watch the entire webinar, please click here.

Potential side effects of Spravato®

Spravato® has a somewhat favorable side effect profile in that its side effects aren’t generally associated with the typical side effects patients experience with antidepressants, such as weight gain or sexual dysfunction. Most side effects are associated with the administration of Spravato®, such as increased blood pressure, disassociation, and sedation. Because of this, Spravato® nasal spray is self-administered by the patient under the direct supervision of a health care provider at a certified Spravato® treatment center2.

Watch to learn more about potential side effects:

To watch the entire webinar, please click here.

Barriers to offering Spravato®

  1. Insurance/prior authorization – Coverage for Spravato® varies by insurance or Medicaid provider, with most requiring prior authorization and proof of two failed trials of optimally dosed antidepressant monotherapy.
  2. Transportation – Patients are advised to wait one full day to drive after receiving Spravato®, requiring them to find alternate transportation on the day of administration.
  3. Staffing shortages – Administering Spravato® requires a health care professional to monitor the patient receiving Spravato® for two hours after the drug is administered.

Watch to learn more about how to overcome potential barriers:

To watch the entire webinar, please click here.

How to offer Spravato® as a treatment option

Spravato® can only be administered in health care settings that are certified through the Spravato® Risk Evaluation and Mitigation Strategy (REMS) program. The certification requirement applies to both the medical offices and/or clinics where Spravato® is administered and the dispensing pharmacy3.

Watch to learn more about becoming a certified Spravato® treatment center:

To watch the entire webinar, please click here.

All Genoa Healthcare pharmacies are certified in the Spravato® REMS program and can help you and your clinic become certified. Please fill out the form below and we’ll be in touch.

Ready to get started?

Have questions about Spravato® or interested in becoming a certified Spravato® treatment center? Fill out for the form below and we’ll be in touch.

"*" indicates required fields

Name*
City
State
This field is for validation purposes and should be left unchanged.

[1]: For information on Spravato® dosing, administration and frequency click here: https://www.spravatohcp.com/dosing-spravato-trd

[2]: For information on potential side effects, click here: https://www.spravato.com/patient-education

[3]: For more information on the certified REMS program, click here: https://www.spravatohcp.com/spravato-rems-certification

Recent Posts


  • Blog Post
A foundation to build on: 3 ways an engaged pharmacy partner helps you deliver whole-person health

A recent survey found that nearly 60% of behavioral health, primary care and complex care providers reported that their organization currently offered or had plans to begin offering integrated care...

  • Clinical Insights
  • Webinar
Understanding Tardive Dyskinesia: What you need to know

Tardive Dyskinesia (TD) – a neurological disorder associated with prolonged use of antipsychotic medications – affects over 600,000 people annually. Wondering what this means for the people you serve? Genoa...

  • Blog Post
340B 101: What your clinic needs to know

For qualified clinics and organizations, the 340B Drug Pricing Program offers savings on prescription drug costs, helping boost offerings and outcomes for people who need it most. Wondering if your...

Genoa pharmacist discussing medications with clinic partner
  • Blog Post
Back to basics: 3 benefits of partnering with a pharmacy and steps for getting started

Your team works hard to give the best care possible to the people you serve and partnering with a pharmacy can empower your staff to make an even bigger impact....